Levels of TNF-alpha, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo

Basit Öğe Kaydı
dc.contributor.authorKaragun, Ebru
dc.contributor.authorBaysak, Sevim
dc.date.accessioned2021-12-01T18:47:41Z
dc.date.available2021-12-01T18:47:41Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractObjectives Vitiligo is an autoimmune disease, and its pathogenesis involves changes in cytokine levels in the affected patients. Tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-17 from pro-inflammatory cytokines, IL-37 in a recently detected anti-inflammatory activity. The aim of our study was to determine serum TNF-alpha, IL-6, IL-17, IL-37 levels in patients with vitiligo to understand their possible roles in the disease etiology and to compare the results with the healthy controls. Methods The study included 48 generalized vitiligo patients who were diagnosed with vitiligo, had an increase in the lesions within the last 3 months, and did not receive any systemic or topical treatment during this period; furthermore, 18 healthy controls were included. Results Patient group: n = 48, mean age = 30.48 +/- 9.86 years; control group: n = 18, mean age = 28.27 +/- 9.66 years. Individuals in the patient group had significantly higher serum levels of IL-37(t = 3.90, p < .001), IL-6 (t = 3.39, p < .05), IL-17 (t = 2.08, p < .05), and TNF-alpha (t = 4.69 p < .001) than in the control group. Conclusion The high levels of (pro-anti) inflammatory cytokines in vitiligo patients draw attention to the importance of cytokines in the pathogenesis of the disease.en_US
dc.identifier.doi10.1080/13685538.2020.1806814
dc.identifier.endpage1492en_US
dc.identifier.issn1368-5538
dc.identifier.issn1473-0790
dc.identifier.issue5en_US
dc.identifier.pmid33191834en_US
dc.identifier.scopus2-s2.0-85096141753en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1487en_US
dc.identifier.urihttps://doi.org/10.1080/13685538.2020.1806814
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10347
dc.identifier.volume23en_US
dc.identifier.wosWOS:000589832300001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofAging Maleen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTNF-&#945en_US
dc.subjectIL-6en_US
dc.subjectIL-17en_US
dc.subjectIL-37en_US
dc.subjectpathogenesisen_US
dc.subjectvitiligoen_US
dc.subjectNecrosis-Factor-Alphaen_US
dc.subjectCellsen_US
dc.subjectInterleukin-37en_US
dc.subjectPathogenesisen_US
dc.subjectSerumen_US
dc.subjectTh17en_US
dc.titleLevels of TNF-alpha, IL-6, IL-17, IL-37 cytokines in patients with active vitiligoen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10347.pdf
Boyut:
732.33 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu